Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Jun;89(6):1923–1930. doi: 10.1172/JCI115798

Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.

K E Ugen 1, J J Goedert 1, J Boyer 1, Y Refaeli 1, I Frank 1, W V Williams 1, A Willoughby 1, S Landesman 1, H Mendez 1, A Rubinstein 1, et al.
PMCID: PMC295892  PMID: 1601999

Abstract

The observation that approximately 70% of HIV-infected pregnant women do not transmit infection vertically suggests that antibody therapy may be effective in the prevention of transmission of HIV infection from mother to child. Currently, there is an incomplete understanding of the processes involved in vertical transmission of HIV infection. The elucidation of the serological basis of maternal immunity as it relates to protection from vertical transmission is the goal of this study. We have screened 20 maternal sera from HIV+ individuals of known vertical transmission status for reactivity with 31 peptides spanning the entire envelope glycoprotein of HIV-1. Of interest was reactivity to regions outside of the V3 loop of gp120. The findings have been examined in relationship to transmission status, as well as to in vitro anti-HIV-1 biological activity. Our results indicate that lack of vertical transmission is correlated with high viral neutralization activity, but not with antisyncytial activity nor with binding to the V3 peptides examined in this study. Also, the transmission group bound to fewer gp41 peptides when compared with the nontransmission group, suggesting that immune responses to gp41 may be important in preventing transmission. These findings may provide insights into the design of passive immunotherapies.

Full text

PDF
1923

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auger I., Thomas P., De Gruttola V., Morse D., Moore D., Williams R., Truman B., Lawrence C. E. Incubation periods for paediatric AIDS patients. Nature. 1988 Dec 8;336(6199):575–577. doi: 10.1038/336575a0. [DOI] [PubMed] [Google Scholar]
  2. Barnes D. M. Grim projections for AIDS epidemic. Science. 1986 Jun 27;232(4758):1589–1590. doi: 10.1126/science.3715462. [DOI] [PubMed] [Google Scholar]
  3. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  4. Bolognesi D. P. HIV antibodies and vaccine design. AIDS. 1989;3 (Suppl 1):S111–S118. doi: 10.1097/00002030-198901001-00016. [DOI] [PubMed] [Google Scholar]
  5. Broliden P. A., Moschese V., Ljunggren K., Rosen J., Fundaro C., Plebani A., Jondal M., Rossi P., Wahren B. Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers. AIDS. 1989 Sep;3(9):577–582. doi: 10.1097/00002030-198909000-00004. [DOI] [PubMed] [Google Scholar]
  6. Centers for Disease Control (CDC) Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep. 1987 Apr 24;36(15):225-30, 235-6. [PubMed] [Google Scholar]
  7. Centers for Disease Control (CDC) Update: serologic testing for antibody to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1988 Jan 8;36(52):833-40, 845. [PubMed] [Google Scholar]
  8. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. doi: 10.1002/j.1460-2075.1986.tb04607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cowan M. J., Hellmann D., Chudwin D., Wara D. W., Chang R. S., Ammann A. J. Maternal transmission of acquired immune deficiency syndrome. Pediatrics. 1984 Mar;73(3):382–386. [PubMed] [Google Scholar]
  10. Dalgleish A. G., Chanh T. C., Kennedy R. C., Kanda P., Clapham P. R., Weiss R. A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology. 1988 Jul;165(1):209–215. doi: 10.1016/0042-6822(88)90674-5. [DOI] [PubMed] [Google Scholar]
  11. Devash Y., Calvelli T. A., Wood D. G., Reagan K. J., Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci U S A. 1990 May;87(9):3445–3449. doi: 10.1073/pnas.87.9.3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Engvall E. Enzyme immunoassay ELISA and EMIT. Methods Enzymol. 1980;70(A):419–439. doi: 10.1016/s0076-6879(80)70067-8. [DOI] [PubMed] [Google Scholar]
  13. Faulkner-Valle G. P., De Rossi A., Dalla Gassa O., Chieco-Bianchi L. LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals. Tumori. 1986 Jun 30;72(3):219–224. doi: 10.1177/030089168607200301. [DOI] [PubMed] [Google Scholar]
  14. Gallo R. C., Sarin P. S., Gelmann E. P., Robert-Guroff M., Richardson E., Kalyanaraman V. S., Mann D., Sidhu G. D., Stahl R. E., Zolla-Pazner S. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):865–867. doi: 10.1126/science.6601823. [DOI] [PubMed] [Google Scholar]
  15. Goedert J. J., Mendez H., Drummond J. E., Robert-Guroff M., Minkoff H. L., Holman S., Stevens R., Rubinstein A., Blattner W. A., Willoughby A. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet. 1989 Dec 9;2(8676):1351–1354. doi: 10.1016/s0140-6736(89)91965-x. [DOI] [PubMed] [Google Scholar]
  16. Jovaisas E., Koch M. A., Schäfer A., Stauber M., Löwenthal D. LAV/HTLV-III in 20-week fetus. Lancet. 1985 Nov 16;2(8464):1129–1129. doi: 10.1016/s0140-6736(85)90720-2. [DOI] [PubMed] [Google Scholar]
  17. Koff W. C., Hoth D. F. Development and testing of AIDS vaccines. Science. 1988 Jul 22;241(4864):426–432. doi: 10.1126/science.3293212. [DOI] [PubMed] [Google Scholar]
  18. Lane H. C., Fauci A. S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985;3:477–500. doi: 10.1146/annurev.iy.03.040185.002401. [DOI] [PubMed] [Google Scholar]
  19. Lewis S. H., Reynolds-Kohler C., Fox H. E., Nelson J. A. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet. 1990 Mar 10;335(8689):565–568. doi: 10.1016/0140-6736(90)90349-a. [DOI] [PubMed] [Google Scholar]
  20. Ljunggren K., Moschese V., Broliden P. A., Giaquinto C., Quinti I., Fenyö E. M., Wahren B., Rossi P., Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis. 1990 Feb;161(2):198–202. doi: 10.1093/infdis/161.2.198. [DOI] [PubMed] [Google Scholar]
  21. Parekh B. S., Shaffer N., Pau C. P., Abrams E., Thomas P., Pollack H., Bamji M., Kaul A., Schochetman G., Rogers M. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study. AIDS. 1991 Oct;5(10):1179–1184. doi: 10.1097/00002030-199110000-00004. [DOI] [PubMed] [Google Scholar]
  22. Pierce S. K., Klinman N. R. Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses. J Exp Med. 1976 Nov 2;144(5):1254–1262. doi: 10.1084/jem.144.5.1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pizzo P. A., Eddy J., Faloon J. Acquired immune deficiency syndrome in children. Current problems and therapeutic considerations. Am J Med. 1988 Aug 29;85(2A):195–202. [PubMed] [Google Scholar]
  24. Romano C., Williams W. V., Fischberg D. J., Cocero N., Weiner D. B., Greene M. I., Molinoff P. B. Subtype-selective immunoprecipitation of the beta 2-adrenergic receptor. J Neurochem. 1989 Aug;53(2):362–369. doi: 10.1111/j.1471-4159.1989.tb07343.x. [DOI] [PubMed] [Google Scholar]
  25. Rossi P., Moschese V., Broliden P. A., Fundaró C., Quinti I., Plebani A., Giaquinto C., Tovo P. A., Ljunggren K., Rosen J. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8055–8058. doi: 10.1073/pnas.86.20.8055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sawyer L. A., Katzenstein D. A., Hendry R. M., Boone E. J., Vujcic L. K., Williams C. C., Zeger S. L., Saah A. J., Rinaldo C. R., Jr, Phair J. P. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Mar;6(3):341–356. doi: 10.1089/aid.1990.6.341. [DOI] [PubMed] [Google Scholar]
  27. Sprecher S., Soumenkoff G., Puissant F., Degueldre M. Vertical transmission of HIV in 15-week fetus. Lancet. 1986 Aug 2;2(8501):288–289. doi: 10.1016/s0140-6736(86)92110-0. [DOI] [PubMed] [Google Scholar]
  28. Thomas E. K., Weber J. N., McClure J., Clapham P. R., Singhal M. C., Shriver M. K., Weiss R. A. Neutralizing monoclonal antibodies to the AIDS virus. AIDS. 1988 Feb;2(1):25–29. doi: 10.1097/00002030-198802000-00004. [DOI] [PubMed] [Google Scholar]
  29. Vujcic L. K., Shepp D. H., Klutch M., Wells M. A., Hendry R. M., Wittek A. E., Krilov L., Quinnan G. V., Jr Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis. 1988 May;157(5):1047–1050. doi: 10.1093/infdis/157.5.1047. [DOI] [PubMed] [Google Scholar]
  30. Weber J. N., Clapham P. R., Weiss R. A., Parker D., Roberts C., Duncan J., Weller I., Carne C., Tedder R. S., Pinching A. J. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987 Jan 17;1(8525):119–122. doi: 10.1016/s0140-6736(87)91964-7. [DOI] [PubMed] [Google Scholar]
  31. Wendler I., Bienzle U., Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987 Summer;3(2):157–163. doi: 10.1089/aid.1987.3.157. [DOI] [PubMed] [Google Scholar]
  32. Williams W. V., Guy H. R., Rubin D. H., Robey F., Myers J. N., Kieber-Emmons T., Weiner D. B., Greene M. I. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6488–6492. doi: 10.1073/pnas.85.17.6488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ziegler J. B., Cooper D. A., Johnson R. O., Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet. 1985 Apr 20;1(8434):896–898. doi: 10.1016/s0140-6736(85)91673-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES